Acrivon Therapeutics, Inc. (ACRV)

NASDAQ: ACRV · Real-Time Price · USD

2.070

-0.080 (-3.72%)

Aug 28, 2026, 1:40 PM EDT - Market open

Acrivon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-74.23	-77.91	-80.56	-60.39	-31.17	-16.24
Depreciation & Amortization	1.5	1.36	1.01	0.54	0.36	0.04
Loss (Gain) From Sale of Investments	0.32	-0.44	-3.78	-3.32	-0.7	-
Stock-Based Compensation	11.4	14.72	14.29	11.62	2.19	0.5
Other Operating Activities	1.07	1.03	0.93	0.78	0.73	1.4
Change in Accounts Payable	-0.14	1.54	-3.59	3.61	-0.25	0.8
Change in Other Net Operating Assets	-2.84	-3.96	6.02	4.53	-1.29	-0.47
Operating Cash Flow	-62.92	-63.67	-65.67	-42.64	-30.12	-13.98
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-1.22	-1.67	-2.77	-1.29	-2.17	-0.24
Investment in Securities	56.73	67.77	-49	52.01	-139.51	-
Investing Cash Flow	55.51	66.1	-51.77	50.72	-141.68	-0.24

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Issuance of Common Stock	7.31	0	70.09	0.78	104.48	0
Repurchase of Common Stock	-0.38	-0.75	-2.52	-1.3	-	-
Other Financing Activities	-0	-	53.46	-1.03	-2.77	-
Financing Cash Flow	6.93	-0.75	121.03	-1.55	101.71	112.22

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Cash Flow	-0.48	1.69	3.59	6.52	-70.08	98

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-64.14	-65.33	-68.44	-43.93	-32.28	-14.22
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-1.63	-1.70	-2.02	-1.99	-7.83	-8.16
Levered Free Cash Flow	-39.82	-39.54	-39.41	-22.33	-20.03	-8.79
Unlevered Free Cash Flow	-39.82	-39.54	-39.41	-22.33	-20.03	-8.79

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Change in Working Capital	-2.98	-2.43	2.44	8.14	-1.53	0.33

SEC Filings: 10-K · 10-Q